Pembro With Radiation With or Without Olaparib

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

July 2, 2026

Study Completion Date

July 2, 2029

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Pembrolizumab

Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.

DRUG

Olaparib

200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.

DRUG

Androgen Deprivation Therapy

Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.

RADIATION

Radiation Therapy

Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.

Trial Locations (2)

40536

RECRUITING

University of Kentucky, Lexington

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Zin W Myint

OTHER